Sichuan Kelun-Biotech Biopharmaceutical Co (HKSE:06990) Equity-to-Asset : 0.66 (As of Dec. 2023)

View and export this data going back to 2023. Start your Free Trial

What is Sichuan Kelun-Biotech Biopharmaceutical Co Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Sichuan Kelun-Biotech Biopharmaceutical Co's Total Stockholders Equity for the quarter that ended in Dec. 2023 was HK$2,548.0 Mil. Sichuan Kelun-Biotech Biopharmaceutical Co's Total Assets for the quarter that ended in Dec. 2023 was HK$3,838.9 Mil.

The historical rank and industry rank for Sichuan Kelun-Biotech Biopharmaceutical Co's Equity-to-Asset or its related term are showing as below:

HKSE:06990' s Equity-to-Asset Range Over the Past 10 Years
Min: -3.25 Med: -3.25 Max: 0.66
Current: 0.66

During the past 3 years, the highest Equity to Asset Ratio of Sichuan Kelun-Biotech Biopharmaceutical Co was 0.66. The lowest was -3.25. And the median was -3.25.

HKSE:06990's Equity-to-Asset is ranked worse than
50.16% of 1565 companies
in the Biotechnology industry
Industry Median: 0.67 vs HKSE:06990: 0.66

Sichuan Kelun-Biotech Biopharmaceutical Co Equity-to-Asset Historical Data

The historical data trend for Sichuan Kelun-Biotech Biopharmaceutical Co's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sichuan Kelun-Biotech Biopharmaceutical Co Equity-to-Asset Chart

Sichuan Kelun-Biotech Biopharmaceutical Co Annual Data

Trend

Dec21

Dec22

Dec23

Equity-to-Asset

-3.25

0.66

Sichuan Kelun-Biotech Biopharmaceutical Co Quarterly Data
	Sep21	Dec21	Jun22	Sep22	Dec22	Jun23	Dec23
Equity-to-Asset	Get a 7-Day Free Trial			-	-2.48	-3.25	-0.21	0.66

Competitive Comparison of Sichuan Kelun-Biotech Biopharmaceutical Co's Equity-to-Asset

For the Biotechnology subindustry, Sichuan Kelun-Biotech Biopharmaceutical Co's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sichuan Kelun-Biotech Biopharmaceutical Co's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sichuan Kelun-Biotech Biopharmaceutical Co's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Sichuan Kelun-Biotech Biopharmaceutical Co's Equity-to-Asset falls into.

Sichuan Kelun-Biotech Biopharmaceutical Co Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Sichuan Kelun-Biotech Biopharmaceutical Co's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )	=	Total Stockholders Equity	/	Total Assets
	=	2547.955	/	3838.896
	=	0.66

Sichuan Kelun-Biotech Biopharmaceutical Co's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )	=	Total Stockholders Equity	/	Total Assets
	=	2547.955	/	3838.896
	=

Sichuan Kelun-Biotech Biopharmaceutical Co (HKSE:06990) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.

Sichuan Kelun-Biotech Biopharmaceutical Co Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Sichuan Kelun-Biotech Biopharmaceutical Co's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Sichuan Kelun-Biotech Biopharmaceutical Co (HKSE:06990) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sichuan Kelun-Biotech Biopharmaceutical Co Ltd (HKSE:06990) » Definitions » Equity-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 666 Xinhua Avenue, Chengdu Cross-Strait Science and Technology Industry Development Park, Wenjiang, Sichuan, Chengdu, CHN

Website

http://www.kelun-biotech.com

Sichuan Kelun-Biotech Biopharmaceutical Co Ltd is an innovative biopharmaceutical company committed to the R&D, manufacturing and commercialization of novel drugs to address medical needs in China and globally. It is one of the first movers in the development of antibody-drug conjugates (ADCs), with over a decade of accumulated experience in ADC development. The company takes a systematic, indication-oriented approach to target the world's prevalent or hard-to-treat cancers, and other diseases and conditions affecting a large and underserved population.

Sichuan Kelun-Biotech Biopharmaceutical Co (HKSE:06990) Headlines

No Headlines